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Abstract
Liquid cultures of the basidiomycetous fungus Gloeophyllum striatum were employed to study the biodegradation
of pradofloxacin, a new veterinary fluoroquinolone antibiotic carrying a CN group at position C-8. After 16 days of
incubation, metabolites were purified by micro-preparative high-performance liquid chromatography. Four
metabolites could be identified by co-chromatography with chemically synthesized standards. The chemical
structures of three compounds were resolved by
1H-nuclear magnetic resonance spectroscopy plus infrared
spectroscopy in one case. All metabolites were confirmed by high resolution mass spectrometry-derived molecular
formulae. They comprised compounds in which the carboxyl group or the fluorine atom had been exchanged for
a hydroxyl group. Furthermore, replacement of the CN group and the intact amine moiety by a hydroxyl group as
well as degradation of the amine substituent were observed. The chemical structure of a catechol-type
fluoroquinolone metabolite (F-5) could be fully defined for the first time. The latter initiated a hypothetical
degradation sequence providing a unique metabolite, F-13, which consisted of the cyclopropyl-substituted
pyridone ring still carrying C-7 and C-8 of pradofloxacin, now linked by a double bond and substituted by a
hydroxyl and the CN group, respectively. Most likely, all reactions were hydroxyl radical-driven. Metabolite F-13
proves fungal cleavage of the aromatic fluoroquinolone core for the first time. Hence, two decades after the
emergence of the notion of the non-biodegradability of fluoroquinolones, fungal degradation of all key structural
elements has been proven.
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Introduction
Pradofloxacin (PRA), a new fluoroquinolone (FQ) drug,
is used to treat bacterial infections in cats and dogs Lit-
ster et al. 2007;Mueller and Stephan 2007. It shares the
core structure of common cyclopropyl-type FQs Doma-
gala and Hagen 2003 but carries a cyano group at posi-
tion C-8 and a bi-cyclic amine at C-7, S,S-
pyrrolidinopiperidine ([1S,6S]-2,8-diazabicyclo[4.3.0]non-
8-yl); the latter is also contained in moxifloxacin Peter-
sen 2006. Concerning in vitro antibacterial activity, par-
ticularly low mutant prevention concentrations of PRA
suggest a high potential for preventing the emergence of
resistance under therapy Wetzstein 2005. Both substitu-
ents in combination are essential for its improved effi-
cacy Wetzstein and Hallenbach 2011. Furthermore, the
CN group facilitates hydrolytic elimination of the amine
moiety (i.e., drug inactivation) under the slightly alkaline
conditions present in decaying animal waste Wetzstein
et al. 2009. Hence, PRA should be more readily biode-
gradable and thus ecologically favorable than conven-
tional FQs.
Fungal degradation of FQs such as ciprofloxacin
Wetzstein et al. 1999, enrofloxacin Karl et al. 2006 and
moxifloxacin Petersen 2006 under defined in vitro con-
ditions has been described in detail. However, all find-
ings yet reported concerned decomposition of the amine
substituent located at C-7 and the pyridone part of the
FQ core. Eighty-seven metabolites of enrofloxacin pro-
duced by Gloeophyllum striatum DSM 9592, a basidio-
mycetous fungus causing brown rot decay of wood by
employing a Fenton-type reaction mechanism Jensen et
al. 2001;Qui and Jellison 2004, could be resolved: The
chemical structures of 18 metabolites were fully
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any medium, provided the original work is properly cited.elucidated, while 69 metabolites needed to be postulated
based on their molecular formula, retention time and
the most likely chemical context Karl et al. 2006. Forty-
eight additional metabolites were generated by seven
taxonomically diverse Basidiomycetes indigenous to agri-
cultural sites, including Agrocybe praecox DSM 13167
from soil Wetzstein et al. 2006. Two postulated cis,cis-
muconic acid-type congeners of enrofloxacin, metabo-
lites 78 and 79 in Karl et al. (2006), came closest to
implying aromatic ring cleavage to have occurred. How-
ever, although chemically more stable, the latter meta-
bolites may, alternatively, be formulated as tetra-
hydroxylated constitutional isomers. Hence, stringent
evidence proving biodegradation of the aromatic core
part of a FQ has not yet been reported. Our aim was to
characterize the basic degradation scheme for PRA in G.
striatum and to attempt the identification of new types
of metabolites, to be expected due to the presence of
the cyano group at position C-8.
Materials and methods
Isolation and identification of metabolites
Mycelia of G. striatum DSM 9592 were grown in a four-
fold diluted malt broth, washed and then re-suspended
in a defined mineral medium to give a concentration of
about 2 mg dry weight per mL, as has been described
previously Wetzstein et al. 1997. The culture vessels,
screw-capped 250-mL Duran
® glass bottles, contained
30 mL of mycelial suspension but were otherwise identi-
cal with those described before. PRA was added at 27 ±
0.5 μg/mL, labeled with either 1.4 or 1.9 MBq of [2-
14C]
PRA or [pyrrolidinopiperidine-7-
14C]PRA, respectively
Wetzstein et al. 2009. Both compounds had a radioche-
mical purity of > 98%. Cultures were then incubated at
room temperature in the dark.
14CO2 produced was
quantified as described before Wetzstein et al. 1997.
Emerging metabolites were monitored by high-perfor-
mance liquid chromatography (HPLC), as described
elsewhere Wetzstein et al. 1997. The former eluent sys-
tem was slightly modified in that the aqueous compo-
nent A contained 10 mM ammonium formate, 1%
formic acid and 1% isopropanol; once again, acetonitrile
served as component B. By adding B, component A was
linearly decreased to 94% between 2 and 5 min, then to
85% over 9 min, to 70% over 15 min, to 50% over 5
min, and to 0% over 10 min. A shallower gradient (B)
needed to be applied during co-chromatographic identi-
fication of the metabolites as well as micro-preparative
purification of single metabolites from collected peak
fractions. The HPLC gradient was modified as follows:
By adding compound B, component A was linearly
decreased to 94% over 5 min, to 88% over 10 min, to
82% over 15 min, to 75% over 15 min, and to 50% over
5 min. In order to identify metabolite F-10,
[pyrrolidinopiperidine-7-
14C]PRA needed to be provided
as substrate. In case of F-10, component B consisted of
10% of acetonitrile in methanol (vol/vol). The flow rate
was 1 mL/min, throughout.
Mycelia were separated by centrifugation and the
resulting pellets washed with 50 mL of sterile water.
The combined supernatants were passed through a 0.45
μm pore-size filter, then freeze-dried and re-suspended
in 2 mL of distilled water. Metabolites could be isolated
from such stock solutions by micro-preparative HPLC
and manual collection of the relevant gradient fractions.
After checking purity by HPLC analysis, metabolites
were concentrated again by freeze-drying and re-sus-
pended appropriately for structure determination.
Structure determination
HPLC-mass spectrometry (HPLC-MS) was performed as
described previously Wetzstein et al. 1997. To character-
ize F-10, an isocratic mobile phase was used consisting
of equal volumes of 25 mM ammonium acetate in water
and methanol. Proton nuclear magnetic resonance (
1H-
N M R )s p e c t r aw e r er e c o r d e da t5 0 0M H zi nD 2Oc o n -
taining 5% (vol/vol) of trifluoroacetic acid-d1,w i t ha c e t -
one serving as an internal standard set at δ = 2.16 ppm
Wetzstein et al. 1997. High-resolution mass spectrome-
try (HR-MS) and determination of the molecular for-
mula have been described by Karl et al. (2006). Fourier
transformed infrared spectroscopy (FT-IR) specifically
indicated the presence of the conjugated nitrile group in
PRA by absorbance at 2205 cm
-1. Of metabolite F-13, a
sample of about 10 μg was imbedded in a micro potas-
sium bromide disc. This was analyzed by using a UMA
500 microscope mounted to a FTS 60A spectrometer
(Bio-Rad, Krefeld, Germany).
Results
Metabolites of PRA formed by G. striatum
After 8 weeks,
14CO2 production from [2-
14C]PRA and
[pyrrolidinopiperidine-7-
14C]PRA, applied at 10 μg/mL,
had reached 34.3% ± 2.7% and 6.3% ± 1.0% of the initi-
ally applied
14C-label (average ± SD for three cultures).
The kinetics were almost identical to those described
previously for [2-
14C]enrofloxacin and [piperazine-2,3-
14C]enrofloxacin, respectively. Hence, the data are not
shown in detail, but see Figure 2 in Wetzstein et al.
(1997).
Chemically synthesized reference standards could be
employed to identify F-1, F-6 and F-9 by co-chromato-
graphy (Figure 2). F-1 and F-6 were identical with con-
geners of PRA, mono-hydroxylated at C-3 or C-8,
respectively. Hydroxyl radical-driven elimination of the
CN group, providing metabolite F-6, is notable. F-9 indi-
cated complete degradation of the amine moiety with
the C-7 amino group remaining attached to the FQ core
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Page 2 of 7Figure 1 HPLC elution profiles of concentrated supernatants from cultures of G. striatum metabolizing [2-
14C]PRA after 16 (A) and 42
days (B) of incubation. In trace (B), the sensitivity of detection was increased threefold.
Figure 2 Co-chromatographic identification of PRA metabolites. Elution profiles of chemically synthesized references are shown in traces (A):
8-OH-PRA, F-6; (B): the 7-amino metabolite of PRA, F-9; and (C): the 3-hydroxy-congener of PRA, F-1. Trace (E) represents the elution profile of
concentrated supernatants. In trace (D), concentrated supernatant had been spiked by adding compounds A, B and C to approximately double
their concentrations. Note the reversed order of F-6 and F-9 (as compared to Figure 1), due to the shallower gradient applied; retention times
are summarized in Table 1. Absorbance was recorded at 270 nm.
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Page 3 of 7part (Figure 3). Following isolation of F-1, F-6 and F-9
by micro-preparative HPLC, their structures were con-
firmed by HR-MS-derived molecular formulae and
1H-
N M Ra n a l y s i sa sw e l l( n o ts h o w n ) .M o l e c u l a rw e i g h t s ,
retention times and characteristics of the absorption
spectra of all metabolites are compiled in Table 1.
HPLC analysis of 16-day-old supernatant revealed the
pattern of PRA metabolites produced (Figure 1). Based
on previous findings, six major metabolites were desig-
nated F-1, F-2, F-5, F-6, F-9 and F-13; F denotes a type
of fungal metabolite with proven chemical structure.
Their concentrations amounted to 9% (F-2), 2 to 3% (F-
1, F-5), and about 1% (F-6, F-9, F-13) of the
14C-label
applied. Upon prolonged incubation (e.g., after 42 days),
the concentrations of F-1, F-2, F-6 and F-5 (three mono
and one dihydroxylated congeners, respectively; see
Figure 3 Metabolic scheme for PRA in G. striatum. Degradation routes were initiated by oxidative decarboxylation (A), defluorination (B),
hydroxylation of position C-8 (C), and decomposition of the amine moiety (D) which, alternatively, could be eliminated intact as F-10.
Hypothetical intermediates are marked in grey: twofold oxidation of the pyrogallol-type intermediate is likely to provide a cis,cis-muconic acid-
type metabolite, from which F-13 may be formed after two spontaneous decarboxylations.
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remained essentially constant. At that point, even PRA
had reached the concentration level typical of major
metabolites. Hence, supernatants of four parallel cul-
tures were harvested on day 16. The
14C-label recovered
in the combined supernatants amounted to 92% of the
activity applied.
Due to their instability, no reference compounds were
available of F-2 and F-5. However, the NMR spectrum
of F-2 showed two singlets (Table 2): one, assigned to
the proton at position C-5 (δ = 7.64 ppm), proved the
absence of fluorine, while the other was due to the pro-
ton at C-2. The molecular weight, reduced by two
atomic mass units (Table 1), was consistent with a
replacement of fluorine by a hydroxyl group. For F-5,
only one singlet was observed in the aromatic region of
the NMR spectrum (Table 2): this was to be assigned to
t h ep r o t o na tC - 2 .A ni n c r e a s ei nt h em o l e c u l a rw e i g h t
of 14 (Table 1), implying the replacement of fluorine by
a hydroxyl group and the addition of one oxygen atom
at position C-5, implicated the catechol-type congener
F-5 (Figure 3). The identity of F-2 and F-5 was con-
firmed on the basis of their molecular formulae deter-
mined by HR-MS (data not shown).
Identification of metabolite F-13, 6-[(E/Z)-1-cyano-2-
hydroxyethenyl]-1-cyclopropyl-4-oxo-1,4-dihydro-3-pyri-
dinecarboxylic acid (Figure 3), was based on (i) its exact
mass, [M+H]
+ = 247.0719, equating to the molecular
formula C12H10N2O4; (ii) three singlets in the aromatic
region of the NMR spectrum, assigned to H-5, H-2 and
H-2’ (Table 2); (iii) NMR signals of all protons of the
cyclopropyl moiety (data not shown); and (iv) specific
peaks of absorbance of the CN group at 2189 and 2218
cm
-1 in the FT-IR spectrum. However, whether the
hydroxyl group at C-2’ was located in cis or trans posi-
tion to the CN group remains to be elucidated.
The application of [pyrrolidinopiperdine-7-
14C]PRA as
substrate to be degraded facilitated the identification of
a seventh major metabolite, F-10, the intact pyrrolidino-
piperidine substituent. Its characterization proceeded
exactly as has been described for the piperazine residue
of enrofloxacin; see Figure 4C in Wetzstein et al. (1997).
F-10 was identified by co-chromatography, employing a
chemically synthesized standard (not depicted), and con-
firmed by determination of its molecular weight (Table
1).
It should be mentioned that the quantities of six addi-
tional metabolites of PRA were too small to permit
comprehensive structure elucidation. Retention times
and HR-MS analysis-based molecular formulae sug-
g e s t e dt h ep r e s e n c eo f( i )o n ea d d i t i o n a lc o n g e n e re a c h
of PRA and F-1, most likely carrying a mono and a
dihydroxylated amine substituent; (ii) F-2, to which one
oxygen atom had been added but water eliminated; and
(iii) F-9, in which fluorine was replaced by a hydroxyl
group; a labile ortho-aminophenol-type metabolite
resembling key metabolite 77 of enrofloxacin (see Figure
5 in Karl et al. [2006]).
Discussion
The basic metabolic pathway of PRA, a new veterinary
FQ antibacterial drug, in the brown rot fungus G. stria-
tum was similar to schemes established for other FQs
such as enrofloxacin, ciprofloxacin and moxifloxacin.
Hydroxylated primary metabolites of PRA, each repre-
senting a different class of compounds (Figure 3), were
generated by hydroxyl radical-based decarboxylation (F-
1), defluorination (F-2) and elimination of CN (F-6).
The definitive identification of a catechol-type FQ con-
gener, compound F-5, carrying one hydroxyl group each
at C-5 and C-6, is described here for the first time. This
was facilitated by the CN substituent blocking C-8, in
Table 1 HPLC retention times, pseudomolecular ions in
HPLC-MS, and characteristics of the UV absorption
spectra of [
14C]PRA and its metabolites
Characteristic Values for
PRA F-1 F-2 F-5 F-6 F-9 F-10
b F-13
Retention time (min)
Method A 23.8 20.2 23.3 25.3 28.1 28.6 ~2.4 15.2
Method B 32.0 24.7 31.4 35.2 41.0 38.7 ~2.4 16.8
Pseudomolecular ion
[M+H]
+ (m/z)
a 397 369 395 411 388 288 127 247
UV absorption (nm)
lmax (major) 288 250 288 298 242 272 - 280
lmax (minor) 364
248
278
362
374
376
392
260
374
298
330
328
350
- 320
362
Shoulder 374
340
260
a [M+H]
+ was accompanied by [M+2+H]
+, resulting from the
14C-label;
b Data obtained in an experiment with [pyrrolidinopiperidine-7-
14C]PRA
Table 2
1H-NMR characteristics of the aromatic protons
of PRA and metabolites produced by G. striatum
Chemical Coupling
Compound H assignment shift δ constant J H, F
(ppm) (Hz)
PRA H-2 8.92
H-5 7.87 14.5
F-1 H-2 8.41
H-5 7.96 14.8
F-2 H-2 9.06
H-5 7.64
F-5 H-2 8.81
F-13 H-2 8.80
H-5 7.08
H-2’ 8.81
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ciprofloxacin Wetzstein et al. 1999, for which hydroxyla-
tion of position C-5 was indistinguishable from hydroxy-
lation of C-8. Degradation of the amine substituent is
represented by F-9.
The identification of metabolite F-13, consisting of the
cyclopropyl-substituted pyridone part and C-atoms 7
and 8 of PRA, now linked by a double bond and carry-
ing a hydroxyl and the CN group, respectively, proved
fungal cleavage of the aromatic FQ core for the first
time. The presence of a conjugated CN group was veri-
fied by IR-spectroscopy. Being part of a mesomeric sys-
tem, the CN group is likely to have stabilized metabolite
F-13 sufficiently as to permit its isolation and structure
elucidation. The most likely intermediates, connecting
F-5 with F-13 (Figure 3), imply: (i) hydroxyl radical-
based elimination of the intact amine moiety (F-10), a
reaction already observed for enrofloxacin and ciproflox-
acin Wetzstein et al. 1997; 1999; (ii) twofold oxidation
of the resulting pyrogallol-type intermediate and the for-
mation of a cis,cis-muconic acid-type analog; and (iii)
spontaneous twofold decarboxylation, finally providing
F-13. Metabolite F-13 adds a unique type of compound
to the plethora of 137 known metabolites of enrofloxa-
cin (including the ethylpiperazine residue and CO2) pro-
duced by basidiomycetous fungi Karl et al. 2006;
Wetzstein et al. 2006.
Six major metabolites of enrofloxacin and, in particu-
lar, 8-OH-PRA (F-6) have been shown to essentially
have lost antibacterial activity Wetzstein et al. 2009;
Wetzstein and Hallenbach 2011. Most recent observa-
tions suggest that minimum inhibitory concentrations of
8-OH-PRA may have been slightly (less than twofold)
overestimated, due to its instability at 37°C, resulting in
a half-life of about 2 days (Wetzstein H-G, unpublished
data). Regardless, FQ residues such as those described
herein appear to be unlikely to pose a significant risk
due to selection of resistance in agricultural soils Wetz-
stein et al. 2009;Baquero et al. 2011.
Recently, metabolites of norfloxacin hydroxylated at
position C-6 and C-8 have been reported to be formed
by Microbacterium spp. isolated from wastewater Kim et
al. 2011. Moreover, from 8-OH-norfloxacin, C-8 may be
eliminated by Candida palmioleophila LA-1 Kim et al.,
Abstr 111th Annu Gen Meet Am Soc Microbiol, abstr.
Q-2943, 2011. The corresponding metabolite should be
indicative of a mechanism of aromatic ring cleavage dif-
ferent from that believed to be observed in this study.
Metabolic inactivation of FQs in mammals predomi-
nantly comprises glucuronidation of the carboxyl group
and sulfation of an appropriate secondary amine func-
tion, if present in the amine substituent. Furthermore,
N-4’-dealkylation, formylation and oxide formation as
well as partial degradation of the C-7 amine substituent
have been observed. However, core-hydroxylated meta-
bolites were not reported, as reviewed by Dalhoff and
Bergan (1998). Another major mechanism of FQ inacti-
vation is N-4’-acetylation, in case of enrofloxacin follow-
ing N-4’-deethylation, as catalyzed by the Zygomycete
Mucor ramannianus Parshikov et al. 2000. For G. stria-
tum,o n l yO-acetylated congeners have been observed,
exemplified by metabolites 13 and 62 described by Karl
et al. (2006). Chemically synthesized N-acetyl-PRA pro-
vides for MICs similar to those of 8-OH-PRA (Wetz-
stein H-G, unpublished observation). However, it is
unknown, whether PRA could serve as a substrate for
the bacterial enzymes yet described.
Most notable, acetylation of the piperazine residue of
ciprofloxacin or norfloxacin by environmental strains of
Mycobacterium Adjei et al. 2006ab has not yet been
found in clinical strains. Furthermore, a FQ-resistant
strain of E. coli, isolated from sewage sludge, contained
the aminoglycoside transacetylase gene aac(6’)-Ib-cr and
was capable of modifying ciprofloxacin by acetylation
Jung et al. 2009. This activity was first observed to be a
plasmid-encoded FQ-resistance factor in Gram-negative
species Robicsek et al. 2006. N-acetylation as well as N-
oxide formation Parshikov et al. 2000;Karl et al. 2006
eliminates the positive charge of the amine residue, pre-
sent at physiological pH. The resulting FQ congener is
negatively charged, thus drug accumulation into the
cytoplasm may be restricted or even prevented.
Strangely enough, the apparently complex degradation
scheme described for enrofloxacin Karl et al. 2006;Wetz-
stein et al. 2006 has to be considered a relatively simple
example, compared to degradation patterns to be
expected for PRA, moxifloxacin and any other FQ with
a more complex amine substituent. Giving rise to the
variety of constitutional isomers, the number of discern-
ible H-atoms in the amine moiety, potentially to be
replaced by a hydroxyl group, amounts to four for enro-
floxacin, but already to twelve for the pyrrolidinopiperi-
dine residue of PRA; this structural feature extends to
metabolites carrying a combination of a hydroxyl and a
keto group or even a cleaved amine moiety. Hence, defi-
nitive structure elucidation of such metabolites would
have to be based on isolated compounds and required a
formidable analytical effort.
In independent studies assessing the chemical degra-
dation of enrofloxacin, ciprofloxacin or other FQs, clea-
vage of the aromatic core could not yet be proved
either, if based on metabolite identification. Work on
ciprofloxacin confirmed several key metabolites
observed with G. striatum: (i) F-1, F-2, F-6 and F-9 in a
membrane anodic Fenton-type system (Xiao et al.
[2010]; see also references 19, 22 and 25, therein); (ii)
isatin and anthranilic acid-type metabolites formed dur-
ing ozonation (Dewitte et al. 2008; and (iii) metabolites
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hydroxyl radicals, generated upon UV-irradiation of
TiO2 Paul et al. 2007. Under the latter conditions, clea-
vage of the cyclopropyl moiety was observed as well.
This leaves unexplored fungal degradation of the cyclo-
propyl-substituent, which, however, is a natural product
found, e.g., in the lipids of E. coli Goldfine 1982. Two
decades after the emergence of the notion of the non-
biodegradability of FQs, briefly reviewed by Wetzstein et
al. (2009), fungal degradation of all key structural ele-
ments of a FQ, in particular of the aromatic core, now
has been proven.
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